Juan Antonio Rosario

🟠 When innovation arrives late, patients feel it. When it arrives on time, it transforms. Between 2015 and 2025, I’ve advised over 40 pharma teams across LATAM and the Caribbean. One of the most powerful moments came in 2023, with a team focused on rare respiratory diseases. 👉 They had a promising pipeline for idiopathic pulmonary fibrosis (IPF). 👉 But their message didn’t resonate with physicians or regulators. 👉 The issue wasn’t the product. It was the narrative. 📌 We reframed the strategy: — Used patient-centered storytelling focused on progressive functional loss. — Translated clinical data into tangible impact: forced vital capacity (FVC), quality of life, hope. — Aligned messaging with regulatory and hospital priorities. 📊 Results: — +52% hospital adoption intent. — +39% engagement with clinical leaders. — +28% faster regulatory response 📈 Why does it matter? — In 2025, the FDA (U.S. Food and Drug Administration) approved JASCAYD® (nerandomilast) by Boehringer Ingelheim, the first new treatment for IPF in over 10 years. — A selective PDE4B (Phosphodiesterase 4B) inhibitor with dual antifibrotic and immunomodulatory mechanisms. — Results from the FIBRONEER™–IPF (Idiopathic Pulmonary Fibrosis clinical trial):  ✔️ Significant reduction in FVC (Forced Vital Capacity) decline over 52 weeks.  ✔️ Benefits observable from week two.  ✔️ Favorable safety profile. — Regulatory applications underway in EU (European Union), Japan, and China. 💡 In pharma, innovation isn’t just science. It’s urgency, opportunity, and purpose. FarmaLatam #IPF #MedicalAffairs #RespiratoryInnovation #PurposeDrivenTransformation #PharmaStorytelling 📩 Iván Estuardo Herrera Leal Senior Pharmaceutical Commercial Leader | Customer Experience Consultant LEGO® Serious Play Facilitator | Executive Coach 📞 +502 5203-7374 | +502 3092-2040 ✉️ [email protected] 🔗 https://lnkd.in/eSsVQW5Q 🌐 www.ihlconsulting.net 📚 Sources: Matraz Innova – FDA approval of JASCAYD® Boehringer Ingelheim – FIBRONEER™–IPF trial results Pulmonary Fibrosis Foundation – IPF epidemiology and therapeutic urgency

7

🔹 𝐅𝐫𝐨𝐦 𝐇𝐞𝐚𝐫𝐢𝐧𝐠 𝐇𝐨𝐫𝐧𝐬 𝐭𝐨 𝐀𝐈-𝐏𝐨𝐰𝐞𝐫𝐞𝐝 𝐋𝐢𝐬𝐭𝐞𝐧𝐢𝐧𝐠: 𝐓𝐡𝐞 𝐄𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐡𝐞 𝐒𝐭𝐞𝐭𝐡𝐨𝐬𝐜𝐨𝐩𝐞 🔹⁣ ⁣ I’ve been following with great interest the incredible work that my friends Jhonatan Bringas Dimitriades, MD and Diana van Stijn, MD PhD are leading together with their team at Lapsi Health. Their latest innovation, 𝐊𝐞𝐢𝐤𝐤𝐮 𝟐.𝟎, is far more than just another medical device. For me, it’s a 𝐚 𝐬𝐲𝐦𝐛𝐨𝐥 of how healthcare innovation can blend empathy, intelligence, and technology 🤖❤️⁣ ⁣ As some of you know, I even used the 𝐟𝐢𝐫𝐬𝐭 𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 Keikku as a 𝐬𝐭𝐮𝐝𝐞𝐧𝐭 𝐜𝐚𝐬𝐞 𝐬𝐭𝐮𝐝𝐲 in my course at the Rome Business School 🎓 It perfectly represents the bridge between traditional medicine and the AI-driven future.⁣ ⁣ It took 𝐜𝐞𝐧𝐭𝐮𝐫𝐢𝐞s to move from the 𝐨𝐥𝐝 𝐡𝐞𝐚𝐫𝐢𝐧𝐠 𝐡𝐨𝐫𝐧 to the modern 𝐬𝐭𝐞𝐭𝐡𝐨𝐬𝐜𝐨𝐩𝐞, first 𝐢𝐧𝐯𝐞𝐧𝐭𝐞𝐝 𝐢𝐧 𝟏𝟖𝟏𝟔 𝐛𝐲 𝐑𝐞𝐧é 𝐋𝐚𝐞𝐧𝐧𝐞𝐜 🩺 and astonishingly, it’s still one of the most commonly used tools today and a symbol for doctors.⁣ ⁣ Yet, as I wrote back 𝐢𝐧 𝟐𝟎𝟏𝟖 in my article “𝐃𝐨𝐜𝐭𝐨𝐫’𝐬 𝐍𝐞𝐰 𝐒𝐭𝐞𝐭𝐡𝐨𝐬𝐜𝐨𝐩𝐞 𝐍𝐚𝐦𝐞 𝐢𝐬 𝐀𝐈,” we still rely on 𝐚𝐧 𝐚𝐫𝐜𝐡𝐚𝐢𝐜 𝐢𝐧𝐬𝐭𝐫𝐮𝐦𝐞𝐧𝐭 that neither records nor learns and whose performance can even depend on the hearing ability of aging physicians 👂⁣ ⁣ That’s why 𝐊𝐞𝐢𝐤𝐤𝐮 𝟐.𝟎 represents such 𝐚 𝐪𝐮𝐚𝐧𝐭𝐮𝐦 𝐥𝐞𝐚𝐩 𝐟𝐨𝐫𝐰𝐚𝐫𝐝 🚀⁣ ⁣ 💡 It 𝐥𝐢𝐬𝐭𝐞𝐧𝐬, 𝐥𝐞𝐚𝐫𝐧𝐬, 𝐚𝐧𝐝 𝐰𝐫𝐢𝐭𝐞𝐬.⁣ This 𝐀𝐈-𝐩𝐨𝐰𝐞𝐫𝐞𝐝 𝐬𝐭𝐞𝐭𝐡𝐨𝐬𝐜𝐨𝐩𝐞 detects heart, lung, and gut sounds with precision, drafts clinical notes automatically, and integrates seamlessly into EHRs thus saving time while enhancing diagnostic accuracy.⁣ ⁣ For me, this is more than technology, 𝐢𝐭’𝐬 𝐚 𝐦𝐨𝐯𝐞𝐦𝐞𝐧𝐭.⁣ A movement towards 𝐚𝐮𝐠𝐦𝐞𝐧𝐭𝐞𝐝 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞, where devices not only assist doctors but also preserve data, reduce bias, and extend the reach of care 🌍💙⁣ ⁣ Congratulations again to the visionary minds at Lapsi Health for daring to reinvent one of medicine’s most iconic tools 👏⁣ ⁣ Would you trust an AI stethoscope that listens, thinks, and learns with your doctor? 🤔⁣ ⁣ #AI #HealthTech #MedTech #DigitalHealth #Innovation #FutureOfHealthcare #Startup #MedicalDevices #ArtificialIntelligence #Leadership #Pharma #HealthcareInnovation #Longevity #Wellbeing #PersonalizedHealth #PGEA #PhilippeGerwill⁣ Owais Durrani Professor Shafi Ahmed Rajesh Sivaprakasam Milan Bates MD, FRCS Gustavo Landsberg Valentino Megale, PhD 🥽 Harvey Castro, MD, MBA. Umer Khan M. Dr. Martha Boeckenfeld Dr. Shaikha Almazrouei Dr. Wissam Adada Mubaraka Ibrahim Dr. Asma Al Mannaei Shahrukh Hashmi

92

36 comentarios

⚙️ Alejandro Martinez Galindo: Building the Future of Clinical Research Alejandro Martinez Galindo thrives in moments of transformation. As CIO of Fortrea, he helped lead one of the most complex corporate separations in the life sciences industry—building a global digital foundation from the ground up as the company spun off from Labcorp. With a career that spans leadership roles at General Motors, Walgreens Boots Alliance, and Capri Holdings, Martinez has consistently taken on challenges others avoid. At Fortrea, he’s now leading the development of AI-powered platforms designed to transform how clinical trials are delivered worldwide. 📎 Discover how Alejandro Martinez Galindo is driving digital innovation—and why he hopes more Latinos will engage in the future of clinical research: https://lnkd.in/eu3Dt8dX #CIOLeadership #ClinicalResearch #LatinoLeaders #LatinosinTech

65

CIOs and technology leaders are key players in GenAI strategy. Explore how to assess costs and realize value from GenAI initiatives ➡️ https://gtnr.it/4jCg33q Gartner for IT | #GartnerIT #CIO #GenAI #Innovation

2

The 2026 Playbook: CHROs and AI Leaders Must Co-Architect the Future ‼️ Gartner’s Top 10 Strategic Technology Trends for 2026 aren’t just about tech they are about transformation. 2026 marks a pivotal year where AI-native, hyperconnected organizations will redefine speed, trust, and human potential. 👉Here’s how I see it through the HR & AI leadership lens 👇 1️⃣ The Architect – Building AI-Ready Foundations 🔺AI-Native Development Platforms → “Tiny Teams” using GenAI to code, create, and collaborate. 🔺 AI Supercomputing & Confidential Computing → Powering ethical, data-secure AI at scale. 👉HR takeaway: Upskill teams to work with AI, not around it. Build AI fluency as a core competency, not a niche skill. 2️⃣ The Synthesist – Orchestrating Intelligence Across Systems 🔺Multi-Agent Systems & DSLMs → Domain-specific AI (for HR, Finance, Healthcare) enhancing accuracy and compliance. 🔺 Physical AI → Robots and automation redefining work execution. 👉HR takeaway: Redesign roles for human-AI teaming. Tomorrow’s workforce will manage agents, not spreadsheets. 3️⃣ The Vanguard – Elevating Trust, Security & Governance 🔺Preemptive Cybersecurity, Digital Provenance, and AI Security Platforms → New shields for the AI age. 🔺 Geopatriation → Balancing global innovation with local sovereignty. 👉HR takeaway: Governance must evolve beyond policies into AI ethics frameworks and digital trust cultures. ✅ The Call to Action: As AI transforms how we build, think, and protect CHROs must become AI Synthesists. We cannot just prepare for the future of work we must co-engineer it. Because in 2026, leadership won’t be about managing technology. It will be about humanizing it. ✅ #AI #CHRO #FutureOfWork #GartnerInsights #Leadership #DigitalTransformation #TrustInAI

6

As we wrap up this year's Veeva Commercial Summit in Madrid I am left with a sense of excitement and optimism. It has been great to see the industry come together to reimagine the future of commercial and medical. We were able to showcase how Vault CRM with Veeva AI embedded is transforming CRM for Life Sciences, hear from some of the 100+ live and happy Vault CRM users, and announce a host of new innovations. A major highlight was hearing directly from Moderna on their experience as a Veeva AI early adopter, speeding up MLR review in Veeva PromoMats. With the first commercial use cases going live in December, we also shared the roadmap on how we will scale agents across the full industry cloud. As always, the true stars of the show were our customers presenting their amazing work. Leaders from GSK, Bayer, BioNTech SE, Idorsia Pharmaceuticals Ltd, Boehringer Ingelheim, Bristol Myers Squibb, and many others on stage shared their journeys to Vault CRM with agentic AI at its core and the innovations that it is unlocking. Enjoy the highlights video and check out on-demand Keynotes and Roadmaps: https://lnkd.in/exW9ZTjn See you next year in Copenhagen, 18-19 November 2026! #VeevaSummitEU #VeevaAI #VeevaVaultCRM #LifeSciences

361

7 comentarios

The way we train teams in the pharmaceutical industry is evolving. It’s no longer only about in-person sessions. Today, we are seeing hybrid formats, micro-learning, virtual reality, and even gamification. 💡 In my experience leading medical and commercial teams across Latin America, digital transformation has opened powerful opportunities: • Micro-learning capsules that reinforce key concepts anytime, anywhere. • Virtual sessions that connect distributed teams, keeping alignment and execution strong. This shift is not just about technology — it’s about developing a culture of learning that adapts to the new pace of our industry. As highlighted by TJP Agency, “continuous learning and adaptability are becoming essential in pharma to empower teams and improve patient outcomes.” As leaders, we must reimagine training not as a one-time event, but as a continuous, inspiring experience. #Leadership #Training #Pharma #TJPAGENCY #MedicalDetailing #LearningCulture #DigitalTransformation #AndresViteri

18

Juan Leonardo Negrón, Global Oncology Public Policy Director from Merck, shares key insights on impactful communication and leadership growth. Learn how his vision highlights the power of communication to inspire and guide teams. #PIALeadership2025

4

1 comentario

Big news out of Madrid at Breakthrough 2026! ArisGlobal just announced XDI (NavaX Data Intelligence), a system-agnostic data intelligence layer that listens to signals, not systems. It connects insights across Clinical, Safety, Regulatory, Medical, and Quality without ripping and replacing existing platforms. The real value is shifting critical decisions left. Catching issues earlier, reducing data fragmentation, and surfacing decision-grade intelligence in real time to move faster and stay compliant. This marks a real shift from isolated automation to coordinated intelligence at scale Excited to see the impact XDI will drive. #Pharma #NavaX #AGBreakthrough26 #AI #OperationalizingAI #LifeSciences

3

Learning "what is that you need to learn" becomes a skill itself when navigating new territories. AI goes far beyond technology. It’s about how we choose to use it, how we implement it responsibly, how we debate its implications and also important, how we challenge and even say “no” to it. From technical foundations to digital transformational thinking, the real question becomes: how does a learner turn new AI knowledge into meaningful impact? Not a trend, not a fear to miss the "bus". Continuously ask yourself: What else should I learn? How can I challenge myself to integrate the new with what I already know and push it further? How do I adapt technology to the problem and not vice versa? As always, knowledge is gold, but applied knowledge is power.

7

On the Clinical Interoperability Value through IHE Profiles (1) The sources of this post are the units and exercises developed over three years for the Master's Degree in Digital Health Management and Governance (MGSD) at OBS Business School - Planeta Formación y Universidades (Barcelona), taught jointly with Dr. J.M. Picas; and the work out of models the last five years in the Clinical Interoperability Workshops (CLINWO: Primer & Advanced) at Virtual Campus https://vicoacademy.com/ of Vico Open Modeling. This post is focused on key Question/Answering (Q&A) topics that may be valuable for any "practitioner" involved in interoperability projects. The core point, is the value added by IHE integration profiles to healthcare organizations and their main stakeholders, to improve clinical interoperability, and therefore, medical outcome. We'll review a rigorous analysis of how IHE creates structural transparency in healthcare organizations. Healthcare’s future isn’t just about technology — it’s about trust:  Trust that systems won’t lose your records.  Trust that errors get caught before harm happens.  Trust that your consent matters.  Trust that data serves people, not bureaucracy. IHE builds that trust silently, relentlessly, one transaction at a time. Thanks to IHE, we are facing an accountability revolution. This isn’t surveillance, it’s systemic integrity. Like aviation’s safety evolution, IHE helps healthcare:  Learn from errors transparently  Build trust through verifiable processes  Focus on engineering safety rather than demanding perfection from humans "Just as black boxes made flying the safest way to travel, IHE profiles can make healthcare the safest place to be when you're vulnerable." IHE’s black box capability shifts healthcare from:  REACTIVE: "Who can we blame?"    PROACTIVE: "How do we make this system error-proof?"   Adapted from John D. Halamka, M.D., M.S., Mayo Clinic Our Q&A workflow aims to explain what type of value IHE profiles (actors and transactions) add to healthcare organizations, reviewing the impact on main stakeholders and their relationships:  1. ICTs Vendors  2. ICTs buyers  3. Healthcare Managers  4. Healthcare professionals  5. Regulatory Entities  6. Financial Entities In a next Post, we'll review IHE interoperability key related processes improving medical outcome:  1. Healthcare quality management  2. Exchanging Structured Financial Reports  3. Clinical Trials: Research & Innovation  4. The Citizen as a PRO-ACTIVE Empowered Patient  5. Healthcare Accountability  6. How IHE Profiles Act as Healthcare's Black Box The editor of this post has a fond appreciation with DEEPSEEK AI Team, and the Mayo Foundation for Medical Education and Research. All Q&A has been refined and checked with different sources and the results shows a high degree of consistency and valuable analysis of the multiple domains of clinical interoperability. Enjoy!

27

Accenture has agreed to acquire Verum Partners, expanding our Infrastructure & Capital Projects capabilities in Latin America. By combining Accenture’s advanced AI capabilities with Verum Partners’ on-site execution leadership and industry expertise, together we will help clients deliver capital projects with greater efficiency and predictability—from feasibility to engineering, construction, commissioning and operational handover. Find out more: https://accntu.re/46UsB1W

7

AI in Mexican Healthcare: The Silent Revolution You’re Not Hearing About Artificial Intelligence isn’t coming to Mexican and LATAM healthcare- it’s already here. From AI-assisted diagnostics to smarter telemedicine for remote regions, technology is quietly personalizing medicine and accelerating research in ways that were unimaginable a few years ago. In my latest article for Mexico Business Publishing, I explore: 1) How AI is being piloted to bridge the gap between rural clinics and urban hospitals. 2) Why specific programs tailored to each patient segment - from low-connectivity regions to high-tech urban centers - are critical for success. 3) How pharma leaders can partner with the Health Ministries (i.e. Secretaría de Salud, SSA) to ensure this transformation reaches all populations, not just the most privileged. 4) This is more than a tech trend - it’s a call to action. If we design this revolution with intention, we can build a healthcare model that is more inclusive, more precise, and more resilient. Read (or listen to) the full article here: Article Link: https://lnkd.in/gaJzFWuh Audio Link: https://lnkd.in/ggWiN_GQ I’d love to hear from you: What role should industry and government play in making AI healthcare truly equitable in Mexico and Latin America? #PharmAdvice #BizAdvice #AI #HealthcareInnovation #Pharma #Mexico #PublicHealth #MBN #ExpertOpinion #DigitalHealth #HealthEquity

30

7 comentarios

ePI is quickly becoming a cornerstone of modern, patient-centric healthcare, especially as regions accelerate their digital transformation journeys. I recently reviewed the "LatAm Playbook for ePI Implementation", developed by FIFARMA in collaboration with EFPIA, which provides a comprehensive look at the current state and future prospects of ePI across Latin America and the Caribbean. The Playbook does a strong job of: - Mapping benefits and challenges associated with ePI adoption - Exploring implementation approaches and enabling technologies - Advocating for a structured, step-by-step model that balances flexibility with standardization The long-term opportunity is clear: as shared experience grows, ePI can drive continuous improvement in how product information is accessed, understood, and trusted—ultimately strengthening patient confidence and improving the healthcare experience. Curious to hear from others working in this space: What do you see as the biggest enablers (or blockers) for ePI adoption Globally — policy, technology, or change management? #ePI #DigitalHealth #RegulatoryAffairs #DigitalTransformation #HealthcareInnovation #LatinAmerica #EMEA #electronicproductinformation #ePIL

18

AI helps Mexican government companies cut costs and improve efficiency I am encouraged by the recent progress our public-sector institutions are making in Mexico in leveraging AI to improve service delivery, reduce costs, and accelerate decision‑making. Extending grid backup from 8 to 24 hours, deploying predictive maintenance at scale, and reducing urban transit delays are not just efficiency wins—they reflect a maturing digital governance strategy. I believe this combination of policy, technology, and operations will define the next phase of public sector transformation. Read more: https://lnkd.in/eFRd7e8u #ArtificialIntelligence #DigitalGovernment #SmartGovernance #MexicoInnovation #PublicSectorTransformation #Efficiency Norma Moreno Ximena Cruz Diego Reyes Luis Manuel Encarnación

7